[HTML][HTML] Transcatheter closure of atrial septal defect and patent foramen ovale with Carag bioresorbable septal occluder: first-in-man experience with 24-month follow …

K Sievert, S Bertog, B Söderberg, S Gafoor… - …, 2022 - ncbi.nlm.nih.gov
Transcatheter closure of atrial septal defect and patent foramen ovale with Carag
bioresorbable septal occluder: first-in-man experience with 24-month follow-up - PMC Back …

[引用][C] Transcatheter closure of atrial septal defect and patent foramen ovale with Carag bioresorbable septal occluder: first-in-man experience with 24-month follow …

K Sievert, S Bertog, B Söderberg, S Gafoor… - …, 2022 - discovery.dundee.ac.uk
Transcatheter closure of atrial septal defect and patent foramen ovale with Carag
bioresorbable septal occluder: first-in-man experience with 24-month follow-up …

[引用][C] Transcatheter closure of atrial septal defect and patent foramen ovale with Carag bioresorbable septal occluder: first-in-man experience with 24-month follow …

K Sievert, S Bertog, B Söderberg… - …, 2022 - providence.elsevierpure.com
Transcatheter closure of atrial septal defect and patent foramen ovale with Carag bioresorbable
septal occluder: first-in-man experience with 24-month follow-up — Providence Skip to main …

[引用][C] Transcatheter closure of atrial septal defect and patent foramen ovale with Carag bioresorbable septal occluder: first-in-man experience with 24-month follow …

K Sievert, S Bertog, B Söderberg… - … of EuroPCR in …, 2022 - pubmed.ncbi.nlm.nih.gov
Transcatheter closure of atrial septal defect and patent foramen ovale with Carag
bioresorbable septal occluder: first-in-man experience with 24-month follow-up …

Transcatheter closure of atrial septal defect and patent foramen ovale with Carag bioresorbable septal occluder: first-in-man experience with 24-month follow-up.

K Sievert, S Bertog, B Söderberg, S Gafoor… - … : Journal of Europcr in …, 2022 - europepmc.org
Transcatheter closure of atrial septal defect and patent foramen ovale with Carag bioresorbable
septal occluder: first-in-man experience with 24-month follow-up. - Abstract - Europe PMC Sign …